StreetInsider.com News Articles http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2022, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 13 Apr 2022 12:02:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif StreetInsider.com News Articles http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday Urovant Sciences to Present Interim Data from Phase 2a Study of Potential Novel Gene Therapy, URO-902, and New Analyses of Data from Phase 3 EMPOWUR Extension Trial of GEMTESA® (vibegron) 75 mg at 20 http://www.streetinsider.com/Press+Releases/Urovant+Sciences+to+Present+Interim+Data+from+Phase+2a+Study+of+Potential+Novel+Gene+Therapy%2C+URO-902%2C+and+New+Analyses+of+Data+from+Phase+3+EMPOWUR+Extension+Trial+of+GEMTESA%C2%AE+%28vibegron%29+75+mg+at+20/19911020.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Urovant+Sciences+to+Present+Interim+Data+from+Phase+2a+Study+of+Potential+Novel+Gene+Therapy%2C+URO-902%2C+and+New+Analyses+of+Data+from+Phase+3+EMPOWUR+Extension+Trial+of+GEMTESA%C2%AE+%28vibegron%29+75+mg+at+20/19911020.html for the full story. http://www.streetinsider.com/Press+Releases/Urovant+Sciences+to+Present+Interim+Data+from+Phase+2a+Study+of+Potential+Novel+Gene+Therapy%2C+URO-902%2C+and+New+Analyses+of+Data+from+Phase+3+EMPOWUR+Extension+Trial+of+GEMTESA%C2%AE+%28vibegron%29+75+mg+at+20/19911020.html Wed, 13 Apr 2022 12:02:00 -0400 A.04822809 A.06822034 MYOV UROV Urovant Sciences to Present Interim Data from Phase 2a Study of Potential Novel Gene Therapy, URO-902, and New Analyses of Data from Phase 3 EMPOWUR Extension Trial of GEMTESA® (vibegron) 75 mg at 20 http://www.streetinsider.com/Press+Releases/Urovant+Sciences+to+Present+Interim+Data+from+Phase+2a+Study+of+Potential+Novel+Gene+Therapy%2C+URO-902%2C+and+New+Analyses+of+Data+from+Phase+3+EMPOWUR+Extension+Trial+of+GEMTESA%C2%AE+%28vibegron%29+75+mg+at+20/19911020.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Urovant+Sciences+to+Present+Interim+Data+from+Phase+2a+Study+of+Potential+Novel+Gene+Therapy%2C+URO-902%2C+and+New+Analyses+of+Data+from+Phase+3+EMPOWUR+Extension+Trial+of+GEMTESA%C2%AE+%28vibegron%29+75+mg+at+20/19911020.html for the full story. http://www.streetinsider.com/Press+Releases/Urovant+Sciences+to+Present+Interim+Data+from+Phase+2a+Study+of+Potential+Novel+Gene+Therapy%2C+URO-902%2C+and+New+Analyses+of+Data+from+Phase+3+EMPOWUR+Extension+Trial+of+GEMTESA%C2%AE+%28vibegron%29+75+mg+at+20/19911020.html Wed, 13 Apr 2022 12:02:00 -0400 A.04822809 A.06822034 MYOV UROV Urovant Sciences to Present Interim Data from Phase 2a Study of Potential Novel Gene Therapy, URO-902, and New Analyses of Data from Phase 3 EMPOWUR Extension Trial of GEMTESA® (vibegron) 75 mg at 20 http://www.streetinsider.com/Press+Releases/Urovant+Sciences+to+Present+Interim+Data+from+Phase+2a+Study+of+Potential+Novel+Gene+Therapy%2C+URO-902%2C+and+New+Analyses+of+Data+from+Phase+3+EMPOWUR+Extension+Trial+of+GEMTESA%C2%AE+%28vibegron%29+75+mg+at+20/19911020.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Urovant+Sciences+to+Present+Interim+Data+from+Phase+2a+Study+of+Potential+Novel+Gene+Therapy%2C+URO-902%2C+and+New+Analyses+of+Data+from+Phase+3+EMPOWUR+Extension+Trial+of+GEMTESA%C2%AE+%28vibegron%29+75+mg+at+20/19911020.html for the full story. http://www.streetinsider.com/Press+Releases/Urovant+Sciences+to+Present+Interim+Data+from+Phase+2a+Study+of+Potential+Novel+Gene+Therapy%2C+URO-902%2C+and+New+Analyses+of+Data+from+Phase+3+EMPOWUR+Extension+Trial+of+GEMTESA%C2%AE+%28vibegron%29+75+mg+at+20/19911020.html Wed, 13 Apr 2022 12:02:00 -0400 A.04822809 A.06822034 MYOV UROV Urovant Sciences to Present Interim Data from Phase 2a Study of Potential Novel Gene Therapy, URO-902, and New Analyses of Data from Phase 3 EMPOWUR Extension Trial of GEMTESA® (vibegron) 75 mg at 20 http://www.streetinsider.com/Press+Releases/Urovant+Sciences+to+Present+Interim+Data+from+Phase+2a+Study+of+Potential+Novel+Gene+Therapy%2C+URO-902%2C+and+New+Analyses+of+Data+from+Phase+3+EMPOWUR+Extension+Trial+of+GEMTESA%C2%AE+%28vibegron%29+75+mg+at+20/19911020.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Urovant+Sciences+to+Present+Interim+Data+from+Phase+2a+Study+of+Potential+Novel+Gene+Therapy%2C+URO-902%2C+and+New+Analyses+of+Data+from+Phase+3+EMPOWUR+Extension+Trial+of+GEMTESA%C2%AE+%28vibegron%29+75+mg+at+20/19911020.html for the full story. http://www.streetinsider.com/Press+Releases/Urovant+Sciences+to+Present+Interim+Data+from+Phase+2a+Study+of+Potential+Novel+Gene+Therapy%2C+URO-902%2C+and+New+Analyses+of+Data+from+Phase+3+EMPOWUR+Extension+Trial+of+GEMTESA%C2%AE+%28vibegron%29+75+mg+at+20/19911020.html Wed, 13 Apr 2022 12:02:00 -0400 A.04822809 A.06822034 MYOV UROV Urovant Sciences to Present Interim Data from Phase 2a Study of Potential Novel Gene Therapy, URO-902, and New Analyses of Data from Phase 3 EMPOWUR Extension Trial of GEMTESA® (vibegron) 75 mg at 20 http://www.streetinsider.com/Business+Wire/Urovant+Sciences+to+Present+Interim+Data+from+Phase+2a+Study+of+Potential+Novel+Gene+Therapy%2C+URO-902%2C+and+New+Analyses+of+Data+from+Phase+3+EMPOWUR+Extension+Trial+of+GEMTESA%C2%AE+%28vibegron%29+75+mg+at+20/19911020.html Visit StreetInsider.com at http://www.streetinsider.com/Business+Wire/Urovant+Sciences+to+Present+Interim+Data+from+Phase+2a+Study+of+Potential+Novel+Gene+Therapy%2C+URO-902%2C+and+New+Analyses+of+Data+from+Phase+3+EMPOWUR+Extension+Trial+of+GEMTESA%C2%AE+%28vibegron%29+75+mg+at+20/19911020.html for the full story. http://www.streetinsider.com/Business+Wire/Urovant+Sciences+to+Present+Interim+Data+from+Phase+2a+Study+of+Potential+Novel+Gene+Therapy%2C+URO-902%2C+and+New+Analyses+of+Data+from+Phase+3+EMPOWUR+Extension+Trial+of+GEMTESA%C2%AE+%28vibegron%29+75+mg+at+20/19911020.html Wed, 13 Apr 2022 12:02:00 -0400 A.04822809 A.06822034 MYOV UROV Urovant Sciences to Present Interim Data from Phase 2a Study of Potential Novel Gene Therapy, URO-902, and New Analyses of Data from Phase 3 EMPOWUR Extension Trial of GEMTESA® (vibegron) 75 mg at 20 http://www.streetinsider.com/Business+Wire/Urovant+Sciences+to+Present+Interim+Data+from+Phase+2a+Study+of+Potential+Novel+Gene+Therapy%2C+URO-902%2C+and+New+Analyses+of+Data+from+Phase+3+EMPOWUR+Extension+Trial+of+GEMTESA%C2%AE+%28vibegron%29+75+mg+at+20/19911020.html Visit StreetInsider.com at http://www.streetinsider.com/Business+Wire/Urovant+Sciences+to+Present+Interim+Data+from+Phase+2a+Study+of+Potential+Novel+Gene+Therapy%2C+URO-902%2C+and+New+Analyses+of+Data+from+Phase+3+EMPOWUR+Extension+Trial+of+GEMTESA%C2%AE+%28vibegron%29+75+mg+at+20/19911020.html for the full story. http://www.streetinsider.com/Business+Wire/Urovant+Sciences+to+Present+Interim+Data+from+Phase+2a+Study+of+Potential+Novel+Gene+Therapy%2C+URO-902%2C+and+New+Analyses+of+Data+from+Phase+3+EMPOWUR+Extension+Trial+of+GEMTESA%C2%AE+%28vibegron%29+75+mg+at+20/19911020.html Wed, 13 Apr 2022 12:02:00 -0400 A.04822809 A.06822034 MYOV UROV Urovant Sciences to Present Interim Data from Phase 2a Study of Potential Novel Gene Therapy, URO-902, and New Analyses of Data from Phase 3 EMPOWUR Extension Trial of GEMTESA® (vibegron) 75 mg at 20 http://www.streetinsider.com/Business+Wire/Urovant+Sciences+to+Present+Interim+Data+from+Phase+2a+Study+of+Potential+Novel+Gene+Therapy%2C+URO-902%2C+and+New+Analyses+of+Data+from+Phase+3+EMPOWUR+Extension+Trial+of+GEMTESA%C2%AE+%28vibegron%29+75+mg+at+20/19911020.html Visit StreetInsider.com at http://www.streetinsider.com/Business+Wire/Urovant+Sciences+to+Present+Interim+Data+from+Phase+2a+Study+of+Potential+Novel+Gene+Therapy%2C+URO-902%2C+and+New+Analyses+of+Data+from+Phase+3+EMPOWUR+Extension+Trial+of+GEMTESA%C2%AE+%28vibegron%29+75+mg+at+20/19911020.html for the full story. http://www.streetinsider.com/Business+Wire/Urovant+Sciences+to+Present+Interim+Data+from+Phase+2a+Study+of+Potential+Novel+Gene+Therapy%2C+URO-902%2C+and+New+Analyses+of+Data+from+Phase+3+EMPOWUR+Extension+Trial+of+GEMTESA%C2%AE+%28vibegron%29+75+mg+at+20/19911020.html Wed, 13 Apr 2022 12:02:00 -0400 A.04822809 A.06822034 MYOV UROV Urovant Sciences to Present Interim Data from Phase 2a Study of Potential Novel Gene Therapy, URO-902, and New Analyses of Data from Phase 3 EMPOWUR Extension Trial of GEMTESA® (vibegron) 75 mg at 20 http://www.streetinsider.com/Business+Wire/Urovant+Sciences+to+Present+Interim+Data+from+Phase+2a+Study+of+Potential+Novel+Gene+Therapy%2C+URO-902%2C+and+New+Analyses+of+Data+from+Phase+3+EMPOWUR+Extension+Trial+of+GEMTESA%C2%AE+%28vibegron%29+75+mg+at+20/19911020.html Visit StreetInsider.com at http://www.streetinsider.com/Business+Wire/Urovant+Sciences+to+Present+Interim+Data+from+Phase+2a+Study+of+Potential+Novel+Gene+Therapy%2C+URO-902%2C+and+New+Analyses+of+Data+from+Phase+3+EMPOWUR+Extension+Trial+of+GEMTESA%C2%AE+%28vibegron%29+75+mg+at+20/19911020.html for the full story. http://www.streetinsider.com/Business+Wire/Urovant+Sciences+to+Present+Interim+Data+from+Phase+2a+Study+of+Potential+Novel+Gene+Therapy%2C+URO-902%2C+and+New+Analyses+of+Data+from+Phase+3+EMPOWUR+Extension+Trial+of+GEMTESA%C2%AE+%28vibegron%29+75+mg+at+20/19911020.html Wed, 13 Apr 2022 12:02:00 -0400 A.04822809 A.06822034 MYOV UROV Urovant Sciences Announces Positive Topline Results of Phase 2a Trial of its Potential Novel Gene Therapy, URO-902 http://www.streetinsider.com/Press+Releases/Urovant+Sciences+Announces+Positive+Topline+Results+of+Phase+2a+Trial+of+its+Potential+Novel+Gene+Therapy%2C+URO-902/19736626.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Urovant+Sciences+Announces+Positive+Topline+Results+of+Phase+2a+Trial+of+its+Potential+Novel+Gene+Therapy%2C+URO-902/19736626.html for the full story. http://www.streetinsider.com/Press+Releases/Urovant+Sciences+Announces+Positive+Topline+Results+of+Phase+2a+Trial+of+its+Potential+Novel+Gene+Therapy%2C+URO-902/19736626.html Mon, 07 Mar 2022 11:56:00 -0400 A.04822809 A.22631517 MYOV UROV Urovant Sciences Announces Positive Topline Results of Phase 2a Trial of its Potential Novel Gene Therapy, URO-902 http://www.streetinsider.com/Press+Releases/Urovant+Sciences+Announces+Positive+Topline+Results+of+Phase+2a+Trial+of+its+Potential+Novel+Gene+Therapy%2C+URO-902/19736626.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Urovant+Sciences+Announces+Positive+Topline+Results+of+Phase+2a+Trial+of+its+Potential+Novel+Gene+Therapy%2C+URO-902/19736626.html for the full story. http://www.streetinsider.com/Press+Releases/Urovant+Sciences+Announces+Positive+Topline+Results+of+Phase+2a+Trial+of+its+Potential+Novel+Gene+Therapy%2C+URO-902/19736626.html Mon, 07 Mar 2022 11:56:00 -0400 A.04822809 A.22631517 MYOV UROV Urovant Sciences Announces Positive Topline Results of Phase 2a Trial of its Potential Novel Gene Therapy, URO-902 http://www.streetinsider.com/Press+Releases/Urovant+Sciences+Announces+Positive+Topline+Results+of+Phase+2a+Trial+of+its+Potential+Novel+Gene+Therapy%2C+URO-902/19736626.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Urovant+Sciences+Announces+Positive+Topline+Results+of+Phase+2a+Trial+of+its+Potential+Novel+Gene+Therapy%2C+URO-902/19736626.html for the full story. http://www.streetinsider.com/Press+Releases/Urovant+Sciences+Announces+Positive+Topline+Results+of+Phase+2a+Trial+of+its+Potential+Novel+Gene+Therapy%2C+URO-902/19736626.html Mon, 07 Mar 2022 11:56:00 -0400 A.04822809 A.22631517 MYOV UROV Urovant Sciences Announces Positive Topline Results of Phase 2a Trial of its Potential Novel Gene Therapy, URO-902 http://www.streetinsider.com/Press+Releases/Urovant+Sciences+Announces+Positive+Topline+Results+of+Phase+2a+Trial+of+its+Potential+Novel+Gene+Therapy%2C+URO-902/19736626.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Urovant+Sciences+Announces+Positive+Topline+Results+of+Phase+2a+Trial+of+its+Potential+Novel+Gene+Therapy%2C+URO-902/19736626.html for the full story. http://www.streetinsider.com/Press+Releases/Urovant+Sciences+Announces+Positive+Topline+Results+of+Phase+2a+Trial+of+its+Potential+Novel+Gene+Therapy%2C+URO-902/19736626.html Mon, 07 Mar 2022 11:56:00 -0400 A.04822809 A.22631517 MYOV UROV Urovant Sciences Announces Positive Topline Results of Phase 2a Trial of its Potential Novel Gene Therapy, URO-902 http://www.streetinsider.com/Business+Wire/Urovant+Sciences+Announces+Positive+Topline+Results+of+Phase+2a+Trial+of+its+Potential+Novel+Gene+Therapy%2C+URO-902/19736626.html Visit StreetInsider.com at http://www.streetinsider.com/Business+Wire/Urovant+Sciences+Announces+Positive+Topline+Results+of+Phase+2a+Trial+of+its+Potential+Novel+Gene+Therapy%2C+URO-902/19736626.html for the full story. http://www.streetinsider.com/Business+Wire/Urovant+Sciences+Announces+Positive+Topline+Results+of+Phase+2a+Trial+of+its+Potential+Novel+Gene+Therapy%2C+URO-902/19736626.html Mon, 07 Mar 2022 11:56:00 -0400 A.04822809 A.22631517 MYOV UROV Urovant Sciences Announces Positive Topline Results of Phase 2a Trial of its Potential Novel Gene Therapy, URO-902 http://www.streetinsider.com/Business+Wire/Urovant+Sciences+Announces+Positive+Topline+Results+of+Phase+2a+Trial+of+its+Potential+Novel+Gene+Therapy%2C+URO-902/19736626.html Visit StreetInsider.com at http://www.streetinsider.com/Business+Wire/Urovant+Sciences+Announces+Positive+Topline+Results+of+Phase+2a+Trial+of+its+Potential+Novel+Gene+Therapy%2C+URO-902/19736626.html for the full story. http://www.streetinsider.com/Business+Wire/Urovant+Sciences+Announces+Positive+Topline+Results+of+Phase+2a+Trial+of+its+Potential+Novel+Gene+Therapy%2C+URO-902/19736626.html Mon, 07 Mar 2022 11:56:00 -0400 A.04822809 A.22631517 MYOV UROV Urovant Sciences Announces Positive Topline Results of Phase 2a Trial of its Potential Novel Gene Therapy, URO-902 http://www.streetinsider.com/Business+Wire/Urovant+Sciences+Announces+Positive+Topline+Results+of+Phase+2a+Trial+of+its+Potential+Novel+Gene+Therapy%2C+URO-902/19736626.html Visit StreetInsider.com at http://www.streetinsider.com/Business+Wire/Urovant+Sciences+Announces+Positive+Topline+Results+of+Phase+2a+Trial+of+its+Potential+Novel+Gene+Therapy%2C+URO-902/19736626.html for the full story. http://www.streetinsider.com/Business+Wire/Urovant+Sciences+Announces+Positive+Topline+Results+of+Phase+2a+Trial+of+its+Potential+Novel+Gene+Therapy%2C+URO-902/19736626.html Mon, 07 Mar 2022 11:56:00 -0400 A.04822809 A.22631517 MYOV UROV Urovant Sciences Announces Positive Topline Results of Phase 2a Trial of its Potential Novel Gene Therapy, URO-902 http://www.streetinsider.com/Business+Wire/Urovant+Sciences+Announces+Positive+Topline+Results+of+Phase+2a+Trial+of+its+Potential+Novel+Gene+Therapy%2C+URO-902/19736626.html Visit StreetInsider.com at http://www.streetinsider.com/Business+Wire/Urovant+Sciences+Announces+Positive+Topline+Results+of+Phase+2a+Trial+of+its+Potential+Novel+Gene+Therapy%2C+URO-902/19736626.html for the full story. http://www.streetinsider.com/Business+Wire/Urovant+Sciences+Announces+Positive+Topline+Results+of+Phase+2a+Trial+of+its+Potential+Novel+Gene+Therapy%2C+URO-902/19736626.html Mon, 07 Mar 2022 11:56:00 -0400 A.04822809 A.22631517 MYOV UROV Urovant Sciences Announces Publication in Advances in Therapy of Analyses of Patient-Perceived Meaningfulness of Improvement in Symptom Reduction for Overactive Bladder Patients Treated with GEMTESA® http://www.streetinsider.com/Press+Releases/Urovant+Sciences+Announces+Publication+in+Advances+in+Therapy+of+Analyses+of+Patient-Perceived+Meaningfulness+of+Improvement+in+Symptom+Reduction+for+Overactive+Bladder+Patients+Treated+with+GEMTESA%C2%AE/19373637.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Urovant+Sciences+Announces+Publication+in+Advances+in+Therapy+of+Analyses+of+Patient-Perceived+Meaningfulness+of+Improvement+in+Symptom+Reduction+for+Overactive+Bladder+Patients+Treated+with+GEMTESA%C2%AE/19373637.html for the full story. http://www.streetinsider.com/Press+Releases/Urovant+Sciences+Announces+Publication+in+Advances+in+Therapy+of+Analyses+of+Patient-Perceived+Meaningfulness+of+Improvement+in+Symptom+Reduction+for+Overactive+Bladder+Patients+Treated+with+GEMTESA%C2%AE/19373637.html Mon, 20 Dec 2021 12:11:00 -0400 A.04822809 A.22631517 MYOV UROV Urovant Sciences Announces Publication in Advances in Therapy of Analyses of Patient-Perceived Meaningfulness of Improvement in Symptom Reduction for Overactive Bladder Patients Treated with GEMTESA® http://www.streetinsider.com/Press+Releases/Urovant+Sciences+Announces+Publication+in+Advances+in+Therapy+of+Analyses+of+Patient-Perceived+Meaningfulness+of+Improvement+in+Symptom+Reduction+for+Overactive+Bladder+Patients+Treated+with+GEMTESA%C2%AE/19373637.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Urovant+Sciences+Announces+Publication+in+Advances+in+Therapy+of+Analyses+of+Patient-Perceived+Meaningfulness+of+Improvement+in+Symptom+Reduction+for+Overactive+Bladder+Patients+Treated+with+GEMTESA%C2%AE/19373637.html for the full story. http://www.streetinsider.com/Press+Releases/Urovant+Sciences+Announces+Publication+in+Advances+in+Therapy+of+Analyses+of+Patient-Perceived+Meaningfulness+of+Improvement+in+Symptom+Reduction+for+Overactive+Bladder+Patients+Treated+with+GEMTESA%C2%AE/19373637.html Mon, 20 Dec 2021 12:11:00 -0400 A.04822809 A.22631517 MYOV UROV Urovant Sciences Announces Publication in Advances in Therapy of Analyses of Patient-Perceived Meaningfulness of Improvement in Symptom Reduction for Overactive Bladder Patients Treated with GEMTESA® http://www.streetinsider.com/Press+Releases/Urovant+Sciences+Announces+Publication+in+Advances+in+Therapy+of+Analyses+of+Patient-Perceived+Meaningfulness+of+Improvement+in+Symptom+Reduction+for+Overactive+Bladder+Patients+Treated+with+GEMTESA%C2%AE/19373637.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Urovant+Sciences+Announces+Publication+in+Advances+in+Therapy+of+Analyses+of+Patient-Perceived+Meaningfulness+of+Improvement+in+Symptom+Reduction+for+Overactive+Bladder+Patients+Treated+with+GEMTESA%C2%AE/19373637.html for the full story. http://www.streetinsider.com/Press+Releases/Urovant+Sciences+Announces+Publication+in+Advances+in+Therapy+of+Analyses+of+Patient-Perceived+Meaningfulness+of+Improvement+in+Symptom+Reduction+for+Overactive+Bladder+Patients+Treated+with+GEMTESA%C2%AE/19373637.html Mon, 20 Dec 2021 12:11:00 -0400 A.04822809 A.22631517 MYOV UROV Urovant Sciences Announces Publication in Advances in Therapy of Analyses of Patient-Perceived Meaningfulness of Improvement in Symptom Reduction for Overactive Bladder Patients Treated with GEMTESA® http://www.streetinsider.com/Press+Releases/Urovant+Sciences+Announces+Publication+in+Advances+in+Therapy+of+Analyses+of+Patient-Perceived+Meaningfulness+of+Improvement+in+Symptom+Reduction+for+Overactive+Bladder+Patients+Treated+with+GEMTESA%C2%AE/19373637.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Urovant+Sciences+Announces+Publication+in+Advances+in+Therapy+of+Analyses+of+Patient-Perceived+Meaningfulness+of+Improvement+in+Symptom+Reduction+for+Overactive+Bladder+Patients+Treated+with+GEMTESA%C2%AE/19373637.html for the full story. http://www.streetinsider.com/Press+Releases/Urovant+Sciences+Announces+Publication+in+Advances+in+Therapy+of+Analyses+of+Patient-Perceived+Meaningfulness+of+Improvement+in+Symptom+Reduction+for+Overactive+Bladder+Patients+Treated+with+GEMTESA%C2%AE/19373637.html Mon, 20 Dec 2021 12:11:00 -0400 A.04822809 A.22631517 MYOV UROV Urovant Sciences Announces Publication in Advances in Therapy of Analyses of Patient-Perceived Meaningfulness of Improvement in Symptom Reduction for Overactive Bladder Patients Treated with GEMTESA® http://www.streetinsider.com/Business+Wire/Urovant+Sciences+Announces+Publication+in+Advances+in+Therapy+of+Analyses+of+Patient-Perceived+Meaningfulness+of+Improvement+in+Symptom+Reduction+for+Overactive+Bladder+Patients+Treated+with+GEMTESA%C2%AE/19373637.html Visit StreetInsider.com at http://www.streetinsider.com/Business+Wire/Urovant+Sciences+Announces+Publication+in+Advances+in+Therapy+of+Analyses+of+Patient-Perceived+Meaningfulness+of+Improvement+in+Symptom+Reduction+for+Overactive+Bladder+Patients+Treated+with+GEMTESA%C2%AE/19373637.html for the full story. http://www.streetinsider.com/Business+Wire/Urovant+Sciences+Announces+Publication+in+Advances+in+Therapy+of+Analyses+of+Patient-Perceived+Meaningfulness+of+Improvement+in+Symptom+Reduction+for+Overactive+Bladder+Patients+Treated+with+GEMTESA%C2%AE/19373637.html Mon, 20 Dec 2021 12:11:00 -0400 A.04822809 A.22631517 MYOV UROV Urovant Sciences Announces Publication in Advances in Therapy of Analyses of Patient-Perceived Meaningfulness of Improvement in Symptom Reduction for Overactive Bladder Patients Treated with GEMTESA® http://www.streetinsider.com/Business+Wire/Urovant+Sciences+Announces+Publication+in+Advances+in+Therapy+of+Analyses+of+Patient-Perceived+Meaningfulness+of+Improvement+in+Symptom+Reduction+for+Overactive+Bladder+Patients+Treated+with+GEMTESA%C2%AE/19373637.html Visit StreetInsider.com at http://www.streetinsider.com/Business+Wire/Urovant+Sciences+Announces+Publication+in+Advances+in+Therapy+of+Analyses+of+Patient-Perceived+Meaningfulness+of+Improvement+in+Symptom+Reduction+for+Overactive+Bladder+Patients+Treated+with+GEMTESA%C2%AE/19373637.html for the full story. http://www.streetinsider.com/Business+Wire/Urovant+Sciences+Announces+Publication+in+Advances+in+Therapy+of+Analyses+of+Patient-Perceived+Meaningfulness+of+Improvement+in+Symptom+Reduction+for+Overactive+Bladder+Patients+Treated+with+GEMTESA%C2%AE/19373637.html Mon, 20 Dec 2021 12:11:00 -0400 A.04822809 A.22631517 MYOV UROV Urovant Sciences Announces Publication in Advances in Therapy of Analyses of Patient-Perceived Meaningfulness of Improvement in Symptom Reduction for Overactive Bladder Patients Treated with GEMTESA® http://www.streetinsider.com/Business+Wire/Urovant+Sciences+Announces+Publication+in+Advances+in+Therapy+of+Analyses+of+Patient-Perceived+Meaningfulness+of+Improvement+in+Symptom+Reduction+for+Overactive+Bladder+Patients+Treated+with+GEMTESA%C2%AE/19373637.html Visit StreetInsider.com at http://www.streetinsider.com/Business+Wire/Urovant+Sciences+Announces+Publication+in+Advances+in+Therapy+of+Analyses+of+Patient-Perceived+Meaningfulness+of+Improvement+in+Symptom+Reduction+for+Overactive+Bladder+Patients+Treated+with+GEMTESA%C2%AE/19373637.html for the full story. http://www.streetinsider.com/Business+Wire/Urovant+Sciences+Announces+Publication+in+Advances+in+Therapy+of+Analyses+of+Patient-Perceived+Meaningfulness+of+Improvement+in+Symptom+Reduction+for+Overactive+Bladder+Patients+Treated+with+GEMTESA%C2%AE/19373637.html Mon, 20 Dec 2021 12:11:00 -0400 A.04822809 A.22631517 MYOV UROV Urovant Sciences Announces Publication in Advances in Therapy of Analyses of Patient-Perceived Meaningfulness of Improvement in Symptom Reduction for Overactive Bladder Patients Treated with GEMTESA® http://www.streetinsider.com/Business+Wire/Urovant+Sciences+Announces+Publication+in+Advances+in+Therapy+of+Analyses+of+Patient-Perceived+Meaningfulness+of+Improvement+in+Symptom+Reduction+for+Overactive+Bladder+Patients+Treated+with+GEMTESA%C2%AE/19373637.html Visit StreetInsider.com at http://www.streetinsider.com/Business+Wire/Urovant+Sciences+Announces+Publication+in+Advances+in+Therapy+of+Analyses+of+Patient-Perceived+Meaningfulness+of+Improvement+in+Symptom+Reduction+for+Overactive+Bladder+Patients+Treated+with+GEMTESA%C2%AE/19373637.html for the full story. http://www.streetinsider.com/Business+Wire/Urovant+Sciences+Announces+Publication+in+Advances+in+Therapy+of+Analyses+of+Patient-Perceived+Meaningfulness+of+Improvement+in+Symptom+Reduction+for+Overactive+Bladder+Patients+Treated+with+GEMTESA%C2%AE/19373637.html Mon, 20 Dec 2021 12:11:00 -0400 A.04822809 A.22631517 MYOV UROV Urovant Sciences Announces Publication in Blood Pressure Monitoring of Positive Ambulatory Blood Pressure Study Results for GEMTESA® (vibegron) 75 mg in Overactive Bladder Patients http://www.streetinsider.com/Press+Releases/Urovant+Sciences+Announces+Publication+in+Blood+Pressure+Monitoring+of+Positive+Ambulatory+Blood+Pressure+Study+Results+for+GEMTESA%C2%AE+%28vibegron%29+75+mg+in+Overactive+Bladder+Patients/19174434.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Urovant+Sciences+Announces+Publication+in+Blood+Pressure+Monitoring+of+Positive+Ambulatory+Blood+Pressure+Study+Results+for+GEMTESA%C2%AE+%28vibegron%29+75+mg+in+Overactive+Bladder+Patients/19174434.html for the full story. http://www.streetinsider.com/Press+Releases/Urovant+Sciences+Announces+Publication+in+Blood+Pressure+Monitoring+of+Positive+Ambulatory+Blood+Pressure+Study+Results+for+GEMTESA%C2%AE+%28vibegron%29+75+mg+in+Overactive+Bladder+Patients/19174434.html Mon, 08 Nov 2021 08:00:00 -0400 A.04822809 A.22631517 MYOV UROV